This is a news story, published by ScienceDaily, that relates primarily to COVID-19 news.
For more biology news, you can click here:
more biology newsFor more news from ScienceDaily, you can click here:
more news from ScienceDailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best science news, business news, entertainment news, and much more. If you like biology news, you might also like this article about
Monoclonal antibody SC27. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest other monoclonal antibody news, several other coronaviruses news, biology news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
SC27 monoclonal antibody treatmentScienceDaily
•
79% Informative
Monoclonal antibody SC27 works against a wide range of COVID-19 variants and related coronaviruses, including past, present and potentially future strains of SARS-CoV-2.
The finding opens the possibility of broader, more effective treatments to work against current and future COVID variants.
SC27 could potentially benefit immunocompromised patients who are unable to get vaccines.
VR Score
87
Informative language
92
Neutral language
62
Article tone
formal
Language
English
Language complexity
71
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links